TABLE 1.
Demographic and clinical data of non-PSP participants and PSP patients
| non-PSP |
PSP |
|||||
|---|---|---|---|---|---|---|
| HC | PD | MSA | All PSP | PSP-RS | PSP-P | |
| Participants | 139 | 270 | 43 | 164 | 108 | 56 |
| Sex (men/women) | 65/74 | 168/102 | 24/19 | 96/68 | 55/53 | 41/15 |
| Age at examination (years)a | 65.1 ± 10.7 | 65.2 ± 8.9 | 65.2 ± 8.7 | 70.8 ± 6.1 | 70.2 ± 5.9 | 71.8 ± 6.3 |
| Disease duration (years)a | NA | 6.4 ± 4.3 | 3.5 ± 2.9 | 4.5 ± 2.9 | 3.7 ± 2.1 | 6.1 ± 3.5 |
| Age at onset (year)a | NA | 58.8 ± 9.1 | 61.7 ± 8.3 | 66.2 ± 6.0 | 66.5 ± 5.9 | 65.7 ± 6.2 |
| H-Y scorea | NA | 2.3 ± 0.7 | 3.3 ± 0.7 | 3.4 ± 0.7 | 3.4 ± 0.6 | 3.3 ± 0.8 |
| MDS-UPDRS scorea | NA | 29.4 ± 12.2 | 56.1 ± 15.9 | 43.5 ± 12.6 | 43.1 ± 12.7 | 44.2 ± 12.5 |
PSP-P, progressive supranuclear palsy–parkinsonism; PSP-RS, progressive supranuclear palsy–Richardson’s syndrome; PD, Parkinson’s disease; MSA, multiple system atrophy; HC, healthy controls; MDS-UPDRS, Movement Disorder Society–sponsored revision of the Unified Parkinson’s Disease Rating Scale; H-Y, Hoehn-Yahr; NA, not applicable.
a
P < 0.001 (non-PSP vs PSP) Mann-Whitney test.